Previous research have shown that rapidly dividing cancer cells require higher levels of sugar than healthy cells. This dependency on sugar distinguishes cancer cells from normal cells and is often used as a treatment option to kill cancer cells. In reality, the results have not been encouraging. Not all cancer cell types are sensitive to the removal of sugar, and even for the cancers that are sensitive, sugar depletion only slows down the rate of cancer progression. The pathways that sensitise cancer cells to sugar deprivation remains poorly understood.
They are among the most challenging prostate cancer patients to treat: about 150,000 men worldwide each year whose cancer is aggressive enough to defy standard hormonal therapy, but has not yet spread to the point where it can be seen on scans.
The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutathera is indicated for adult patients with somatostatin receptor-positive GEP-NETs.
In 2018, it is estimated that more than 13,000 women will be diagnosed with cervical cancer, most often with a pap smear, also called a pap test, or a pap smear combined with a screening test for HPV, human papillomavirus. At one point, cervical cancer was one of the most common causes of cancer death for women in the U.S.
The desire to detect cancer before it spreads to other areas of the body remains one of the priorities of the cancer research field. Why? Because, early detection of tumorous cancers could potentially be cured by surveillance and surgery alone, before metastasis occurs.
The oncogene RAS is the most frequently mutated gene of its type in human cancer. Active mutants are found in 60 to 90 percent of cases of pancreatic cancer, and a significant portion of colorectal and lung cancers.